
BeOne Medicines Ltd.: shareholders and insiders
Price
$390.94
November 20, 2026Market cap $43.4B
What Ploutos Investor adds for BeOne Medicines
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Baker Bros. Advisors LPwith 4 more personsShare of class7.80%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Baker Bros. Advisors LPwith 4 more persons | 7.80% | 116M | Sep 16, 20263 filings since Apr 16, 2026 | 13D/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Baker Bros. Advisors LP7.8%From the filing of Sep 16, 2026
Item 4 of this Amendment is supplemented and amended, as the case may be, as follows: On September 14, 2026, the Adviser exercised options to purchase Ordinary Shares or ADS ("Share Options") to purchase 30,768 ADS as a result of the exercise of 15,384 Share Options to purchase ADS at $36.83 per ADS (the "Exercised ADS Options") held directly by each of Ranjeev Krishana and Michael Goller, resulting in the acquisition of a total of 30,768 ADS. Messrs. Krishana and Goller, each of whom is a full-time employee of the Adviser, previously served on the Issuer's board of directors (the "Board") as representatives of the Funds. The policy of the Funds and the Adviser does not permit full-time…
From the filing of Sep 16, 2026
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter-64%
- Millennium Mgmt (Englander)In the quarter-49%
- Renaissance TechnologiesIn the quarter+37%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 520.1K | -64% | $190M | 0.10% |
| Millennium Mgmt (Englander) | 278.7K | -49% | $102M | 0.07% |
| Renaissance Technologies | 139.8K | +37% | $51M | 0.07% |
| D.E. Shaw | 745 | $300.0K | 0.00% | |
| AQR Capital | 1,938 | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 56.2% of the shares in the reported trades were short sales, against 66.1% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 56.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 66.1%
- Change
- -9.9 pts
- Short sales a dayon average, of 168.4K shares
- 94.6K
- More than atof 3,666 US-listed companies, same days
- 71%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 70.8%
- Oct 15, 2026: Short sales 66%
- Oct 16, 2026: Short sales 69.5%
- Oct 19, 2026: Short sales 66.6%
- Oct 20, 2026: Short sales 63.1%
- Oct 21, 2026: Short sales 77.1%
- Oct 22, 2026: Short sales 73.5%
- Oct 23, 2026: Short sales 63.9%
- Oct 26, 2026: Short sales 66%
- Oct 27, 2026: Short sales 64.6%
- Oct 28, 2026: Short sales 65.1%
- Oct 29, 2026: Short sales 72.2%
- Oct 30, 2026: Short sales 50.9%
- Nov 2, 2026: Short sales 50.5%
- Nov 3, 2026: Short sales 76.7%
- Nov 4, 2026: Short sales 48%
- Nov 5, 2026: Short sales 61.4%
- Nov 6, 2026: Short sales 34.8%
- Nov 9, 2026: Short sales 47.1%
- Nov 10, 2026: Short sales 63.6%
- Nov 11, 2026: Short sales 61.5%
- Nov 12, 2026: Short sales 35.4%
- Nov 13, 2026: Short sales 54.6%
- Nov 16, 2026: Short sales 53.7%
- Nov 17, 2026: Short sales 57.1%
- Nov 18, 2026: Short sales 72.2%
- Nov 19, 2026: Short sales 55.2%
- Nov 20, 2026: Short sales 81.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund1.77%
- FXIiShares China Large-Cap ETFWeight in the fund1.60%
- MCHIiShares MSCI China ETFWeight in the fund0.86%
- AIAiShares Asia 50 ETFWeight in the fund0.41%
- CGGOCapital Group Global Growth Equity ETFWeight in the fund0.32%
- IXJiShares Global Healthcare ETFWeight in the fund0.27%
- SCHESchwab Emerging Markets Equity ETFWeight in the fund0.21%
- AAXJiShares MSCI All Country Asia ex Japan ETFWeight in the fund0.19%
- EEMiShares MSCI Emerging Markets ETFWeight in the fund0.18%
- VWOVanguard Emerging Markets Stock Index FundWeight in the fund0.18%
24 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 266
- Q4 2025: Managers 287
- Q1 2026: Managers 283
- Q2 2026: Managers 282
Institutional investors by quarter
The fund managers holding ONC, quarter by quarter, from Q1 2016 to Q2 2025, 38 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 282 managers held 34.97M shares, worth $9.9B. During the quarter 46 opened a position, 47 closed one, 122 added and 68 trimmed.
The largest holders, Q2 2026
- Baker Bros. AdvisorsIn the quarter
- Primecap ManagementIn the quarter+0.7%
- Capital International InvestorsIn the quarter+1.2%
- FMRIn the quarter-33%
- Capital World InvestorsIn the quarter+39%
- Citadel Advisors (Griffin)In the quarter+38%
- Temasek Holdings (Private)In the quarter-2.0%
- Price T Rowe AssociatesIn the quarter+41%
- BlackRockIn the quarter+5.6%
- Millennium Mgmt (Englander)In the quarter+165%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Baker Bros. Advisors | 8.80M | $2.5B | |
| Primecap Management | 5.01M | +0.7% | $1.4B |
| Capital International Investors | 4.21M | +1.2% | $1.2B |
| FMR | 2.48M | -33% | $706M |
| Capital World Investors | 2.25M | +39% | $641M |
| Citadel Advisors (Griffin) | 1.43M | +38% | $406M |
| Temasek Holdings (Private) | 845.7K | -2.0% | $241M |
| Price T Rowe Associates | 758.8K | +41% | $216M |
| BlackRock | 694.6K | +5.6% | $198M |
| Millennium Mgmt (Englander) | 543.3K | +165% | $155M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do BeOne Medicines's filings show?
Who buys and sells is one part of BeOne Medicines's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold ONC?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $190M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.